(European) incidence rate (per 100,000 person-years) increased from 13.3 in 1993 to 21.3 in 2010 with an estimated annual increase of 5.1% in women and 2.1% in men. The increase was most pronounced for tumors of intermediate aggressiveness from 3.3 in 1993 to 7.3 in 2010. The largest annual increases were estimated for the adrenal gland (8.8%), the pancreas (6.9%) and the lungs (6.1%). Conclusion: The incidence of NENs increased. Most primary tumors were found in the lungs or in the gastroenteropancreatic system. The increase in the incidence differed according to the primary site, gender and tumor aggressiveness.
ized by their ability to produce peptides and neuroamines that can cause distinct clinical syndromes. Neuroendocrine cells are scattered throughout the body, hence NENs may arise in most organs. The malignant potential of NENs varies from indolent tumors to highly aggressive carcinomas. The histopathological diagnosis is based on the growth pattern, the uniformity of tumor cells and expression of the immunohistochemical markers synaptophysin and chromogranin A [1] [2] [3] [4] .
During the last few decades, the nomenclature and classification of NENs have changed. These neoplasms have been classified according to their embryologic origin (foregut, midgut or hindgut), according to their morphological features and according to their immunohistochemical properties [5] [6] [7] . There are no uniform classifications of morphology and grading covering all anatomical sites.
The most common primary tumor sites are in the bronchopulmonary system and in the gastrointestinal tract. Studies show geographical [8] [9] [10] [11] and racial [12] [13] [14] differences. A significant number of NENs occur in other anatomical sites [7] , but they are often excluded from population-based studies and our knowledge about their incidence and behavior is sparse.
Recent population-based studies show an increasing incidence of NENs with incidence rates up to 5 cases per 100,000 person-years [13, 15] . The rise in the incidence rate seems to vary with the site of origin and tumor grade [16] . This increase may have several explanations: a real increase in incidence, an increased number of incidental findings due to more extensive use of endoscopic and radiological examinations, increased awareness of NENs among clinicians and pathologists [17] and changes in classification.
The aim of this study was to present incidence rates and trends for all NENs according to the site of origin, including rare types, in Norway from 1993 through 2010.
Materials and Methods
Our analyses were based on NEN cases diagnosed from 1993 through 2010 reported to the Cancer Registry of Norway (CRN). The CRN was established in 1953 and covers the entire Norwegian population (4.3 million in 1993, 4.9 million in 2010 of whom 95% are Caucasian). A unique national identification number given to all inhabitants in Norway ensures unequivocal identification. Medical doctors diagnosing or treating neoplastic disease are mandated by law to report all new cases of cancer as well as benign and premalignant neoplasms of the central nervous system and of endocrine origin including those diagnosed at autopsy. Disease information is received from several different sources, such as clinician reports, pathology and autopsy reports and death certificates [18] . CRN coding based on the received full-text reports is performed by trained personnel. The degree of completeness is estimated to be 98.8% [19] .
We used cancer registry information on topography, morphology and disease dissemination at the time of diagnosis. Morphological groups included as NENs in this study were small cell carcinoma, large cell neuroendocrine carcinoma, Merkel cell carcinoma, carcinoid, islet cell neoplasms, pheochromocytoma/ paraganglioma, medullary carcinoma of the thyroid, neural/neuroblastic neoplasms and 'NEN not otherwise specified' ( table 1 ) . Mixed neuroendocrine-exocrine tumors (both components of at least 30%) were included, while exocrine tumors such as adenocarcinoma with neuroendocrine differentiation (neuroendocrine components less than 30%) were excluded [20] . A total of 65 International Classification of Diseases for Oncology (ICD-O) morphology codes represented these tumor groups. Original CRN coding of morphology was according to the ICD-O second revision [21] (1993-2006) and ICD-O third revision [22] (2007-2010) . Table 1 presents the ICD-O third revision codes for all included NENs. We included tumors diagnosed from 1993 to decrease the impact of altered registration practice in the CRN and changing classifications by limiting the study to the two most recent ICD-O classifications. Tumors up to 2010 were considered because this was the last year with complete data when we started our study.
There is no uniform classification for all anatomical sites, but the most recent grading systems for gastroenteropancreatic (GEP) (WHO 2010) and lung (WHO 2015) NENs [23] [24] [25] can also be indicative of the classification of tumors in other sites. These classifications are based on markers of proliferation, mitotic figures (per 10 high-power fields or per 2 mm 2 ) in light microscopy or immunohistochemical staining of the Ki-67 antigen. Based on the number of mitotic figures or the percentage of Ki-67-positive tumor cells, NENs are graded from 1 to 3, grade 1 being the most differentiated and least aggressive one. Grade 1 and grade 2 NENs are termed neuroendocrine tumors. Grade 3 NENs are termed neuroendocrine carcinomas (NECs) and are the least differentiated and most aggressive neoplasms. A CRN grading variable based on markers of proliferation was not possible as reporting of proliferation indexes was not done until recently. Instead, we divided our 65 NEN morphological types into three tumor aggressiveness groups based on known disease behavior ( table 1 ). We stratified the tumors into a low aggressiveness group (adenomas) and neoplasms with indisputably aggressive behavior into a high aggressiveness group. The remaining neoplasms were defined as intermediately aggressive, roughly corresponding to the present grades 1 and 2 neuroendocrine tumors. In tumor groups where the stratification based on the morphological codes was less forward, we searched the literature for behavior and patient survival before classification into one of the aggressiveness groups [26] [27] [28] [29] [30] [31] [32] .
Our aim was to give a comprehensive presentation of NENs. Thus, we included adenomas and adenocarcinomas of the parathyroid glands and the pituitary gland as well as small cell carcinomas and large cell NECs. However, to facilitate comparison with previous studies, adenomas were omitted in time trend analyses. Insulinomas, appendiceal NENs and pheochromocytomas/paragangliomas have traditionally been classified as benign or malignant based on the absence or presence of metastatic growth. These NENs are now accepted to have malignant potential, and the use of the terminology 'benign' is under debate. We chose to include The stage at the time of the diagnosis is presented as localized disease, regional disease or distant disease based on the aggregation of 10 CRN categories of disease dissemination. Localized disease assumes no disease spread. Regional disease includes microscopic or macroscopic tumor growth into a neighboring structure or in lymph nodes of the same body segment as the primary tumor. Distant disease includes metastasis to any other organ or to lymph nodes of a body segment other than that of the primary tumor. Due to missing data on tumor stage, ranging from 17% missing in the year 2000 to 4% missing in the year 2010, tumor stage was imputed using univariate multiple (m = 100) imputation. The imputation model was an augmented multinomial logistic regression [33] [34] [35] stratified by primary site and tumor aggressiveness, with continuous (c) and indicator (i) predictors: age at diagnosis (c), year of diagnosis (i), time to death or censoring (c) and an indicator of death/censoring (i). For the analysis of time trends in stage distribution, the imputation model was stratified by tumor aggressiveness and two additional predictors where included, i.e. morphological group (i) and an indicator of metastasis (i).
Age-standardized incidence (per 100,000 person-years) rates (ASR) were calculated using direct standardization with the European standard population [36] as weights. Confidence intervals (CI) for the ASR were calculated with the modified gamma limits proposed by Tiwari et al. [37] as implemented in the Stata [38] program distrate [39] . Estimated annual percentage change (EAPC) was calculated using Poisson regression with adjustment for age. In figure 1 a-c, annual ASR were smoothed using lowess [40] with a bandwidth of 0.8. 
Results
A total of 16,075 NENs in 15,955 patients were reported to the CRN from 1993 through 2010. The most common primary tumor sites were the lungs (48.1%) and the GEP system (18.0%). The median age at diagnosis was 65 years (interquartile range 54-74), and 49.5% of the tumors were diagnosed in women. The lowest median age was found in patients with NENs of the nervous system (7 years) and the highest in patients with NENs of the skin (79 years). 
Aggressiveness and Stage

Time Trends
The incidence rate for all NENs increased from 13.3 in 1993 to 21.3 in 2010, with an estimated annual increase of 5.1% (95% CI, 4.6-5.5) in women and 2.1% (95% CI, 1.7-2.5) in men ( fig. 1 a) . The incidence rate for intermediately aggressive tumors increased from 3.3 to 7.3, the estimated annual increase being 5.3% (95% CI, 4.7-5.8). An increase was observed in all common sites. The most pronounced increases were found in the adrenal gland (94% pheochromocytomas), with an estimated annual increase of 8.8% (95% CI, 5.9-11.7), in the pancreas with an increase of 6.9% (95% CI, 5.0-8.9) and in the lungs with an increase of 6.1% (95% CI, 4.7-7.4) ( fig. 1 b) .
The overall incidence rate for tumors of high aggressiveness was stable over the study period, but there were differences according to gender and primary site, with an increasing incidence in women and a falling incidence in men ( fig. 1 c) . This gender difference was mostly due to lung carcinomas showing an EAPC of -1.0 (95% CI, -1.6 to -0.4) in men and 3.0 (95% CI, 2.3-3.7) in women. The incidence rate for NENs of the skin (97% Merkel cell carcinoma) increased in both genders combined by 4.2% (95% CI, 1.7-6.8).
The stage distribution, i.e. localized, regional and distant spread, was relatively stable throughout the study period for tumors of both intermediate and high aggressiveness ( fig. 2 ).
Discussion
The incidence rate of NENs in Norway increased from Figures are ASR with 95% CIs in square brackets. In groups with few cases and an estimated incidence rate <0.03, the number of cases (n) is given. * = The subgroup is not defined.
responding to WHO grades 1 and 2, showing an increase from 3.3 in 1993 to 7.3 in 2010 with the steepest increases for the adrenal gland, the pancreas and the lungs.
We observed higher incidence rates than reported from the US [13] and the Netherlands [16] . Some of this difference may be explained by our inclusion of morphological types such as pheochromocytomas/paragangliomas, medullary thyroid carcinomas and tumors of 'uncertain behavior'. Inclusion of all appendiceal NENs and tumors of 'uncertain behavior' in sites such as the pancreas, where we included all insulinomas, could explain higher incidence rates in the intermediately aggressive tumor group compared to other epidemiological studies [12, 13, 16, 41, 42] .
The steepest increase in NEN incidence rates was observed in intermediately aggressive tumors of the adrenal gland, mostly pheochromocytomas, where the incidence increased by more than fourfold, with the estimated annual increase being 8.8%. Previous studies have reported incidence rates between 0.2 and 0.8 per 100,000 person-years [9, 43, 44] . However, this is, to our knowledge, the first study reporting an incidence rate time trend for tumors of the adrenal gland. There have been no changes in diagnostic criteria or morphological classification for pheochromocytomas to explain the increasing occurrence in the study period. The overall incidence rate of highly aggressive tumors was stable over time. There was an increase in the incidence of lung NECs in women, while there was a decrease in men, as seen in other lung cancers. The largest increase in highly aggressive tumors was found for NECs of the skin with an estimated annual increase of 4.2%. A similar trend was reported in a recent Australian study, the annual increase being 2.6% [45] , and in a population-based study from the Netherlands where a doubled incidence rate for Merkel cell carcinomas from 1993 to 2007 was found [46] .
It has been proposed that the increase in the incidence of NENs might be explained by an increased detection rate. However, there were no endoscopic screening programs in Norway during our study period, but the number of procedures has increased. The utilization of radiological procedures has also increased. From 1993 to 2008, the use of CT scanning in Norway increased almost fourfold from 50 to 194 examinations per 1,000 inhabitants per year [47] . Between 2002 and 2008, the use of MRI increased from 61 to 126 examinations per 1,000 inhabitants per year [48] . Improvements in the CT and MRI technologies together with refinements in the use of contrast in the same period have increased the resolution of the procedures substantially. With this increase in quantity and quality of radiological procedures, an increased detection rate of NENs and a shift towards more patients being diagnosed with small tumors and localized disease would be expected. Information on tumor size was not available. However, we observed a stable stage distribution. A likely explanation for the stable stage distribution could be that improved imaging also better detected disseminated disease at the time of diagnosis. Our findings differ from reports from the SEER database [13, 49] where a relative increase in localized NENs was found, but a recent Canadian study [15] reports a stable incidence of metastatic disease and suggests that the increase in incidence may be due to increased detection. The proportion of missing stage in our study has changed somewhat throughout the period, mainly due to changes in coding practice. This could to some extent distort the estimation of time trends in the stage distribution, which is not fully eliminated by the imputation of missing stage, but we do not believe that this factor influences the stage distribution significantly. Based on our findings, we are not able to conclude whether the observed increase in NEN incidence rates are due to a true increase in occurrence, due to a more extensive use of radiological and endoscopic procedures, due to increased awareness among pathologists and clinicians, due to improved histopathological classification or to a combination of these factors. However, we believe that our findings are indicative of a true increase in incidence.
Our results are based on data from a national cancer registry with a high degree of completeness. Despite the fact that we included more histological types than any previous studies, we may have missed some morphological codes for tumors of neuroendocrine origin. Accordingly, we may have underestimated the incidence rate. Complete data on tumor differentiation were not available. We, therefore, stratified the tumors into three groups of aggressiveness according to their morphological characteristics resembling the WHO grading. Some degree of aggressiveness misclassification may have occurred.
Conclusion
Most primary tumors were found in the lungs or in the GEP system, and the distribution of stage was stable throughout the study period. The incidence rate for neuroendocrine tumors of intermediate aggressiveness, resembling the WHO grades 1 and 2, increased. The steep-est increase was observed for NENs of the adrenal gland, the pancreas and the lungs. The overall incidence rate for tumors of high aggressiveness, corresponding to WHO grade 3 NECs, was stable throughout the study period.
